Home / NEWS / Here's Why CRISPR Therapeutics Has Lost One-Third of Its Value Since September

Here's Why CRISPR Therapeutics Has Lost One-Third of Its Value Since September


Here's Why CRISPR Therapeutics Has Lost One-Third of Its Value Since September


A share offering didn't help. Investors also began to wonder: Was a $2.5 billion market cap justified?


A share offering didn't help. Investors also began to wonder: Was a $2.5 billion market cap justified?


Here's Why CRISPR Therapeutics Has Lost One-Third of Its Value Since September
Here's Why CRISPR Therapeutics Has Lost One-Third of Its Value Since September Here's Why CRISPR Therapeutics Has Lost One-Third of Its Value Since September Reviewed by Unknown on 12:08 PM Rating: 5

No comments:

Subscribe to: Post Comments ( Atom )
Powered by Blogger.